• FDA cleared Merck’s WELIREG with Eisai’s LENVIMA for previously treated adults with advanced clear cell renal cell carcinoma.
• Use targets patients whose disease progressed on a PD-1 or PD-L1 inhibitor.
• Phase 3 LITESPARK-011 showed median PFS of 14.6 months vs 10.6 months with cabozantinib; HR 0.74.
• Overall survival missed statistical significance at final analysis; objective response rate was 53% vs 40%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260924674783) on September 25, 2026, and is solely responsible for the information contained therein.